Illumina last week launched two SNP-based assay panels designed to study genetic variation and function in the major histocompatibility complex region of the human genome, the company said.
The MHC Exon-Centric Panel consists of 1,228 SNPs in or within 10 kb of protein-coding regions, while the MHC Mapping Panel includes 1,293 SNPs evenly distributed across the entire region. The MHC is believed to contribute to many common autoimmune and inflammatory disorders including multiple sclerosis, type-1 diabetes and rheumatoid arthritis, Illumina said.
The panels have been optimized for Illumina's GoldenGate genotyping protocol, and can be used with the company's BeadChip arrays.
Genospectra has launched QuantiGene Plex, a multiplexed gene expression-profiling assay based on the xMAP technology platform from Luminex.
QuantiGene allows researchers to quantify the expression of multiple mRNA targets in a single well without using RNA purification, or reverse transcription, or target amplification, Genospectra said. The company also claims that QuantiGene Plex is able to detect differences in expression in percentages, rather than in fold differences as measured by other technologies.
The company recommends the assay for biomarker analysis, RNA interference studies, microarray validation, and predictive toxicology.
CORRECTION: Last week's product section of BioArray News described Enzo Biochem's BioArray CGH Labeling System incorrectly. The system does not contain bacterial artificial chromosome arrays.